Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.42 |
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | AGER | Q15109 | 2/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22482985 | 0.82 | HDAC6 (0.56) | HDAC6HDAC8HDAC1 | |
| SCHEMBL24472824 | 0.73 | HDAC6 (0.73) | HDAC6HDAC8 | |
| SCHEMBL22482983 | 0.71 | OPRM1 (0.36) | NPC1RAB9AHDAC6OPRM1AGER | |
| SCHEMBL22482981 | 0.65 | HDAC6 (0.65) | NPC1RAB9AHDAC6HDAC8HDAC1 | |
| SCHEMBL22482882 | 0.64 | HDAC6 (0.51) | NPC1RAB9AHDAC6HDAC8HDAC1 | |
| SCHEMBL13479882 | 0.64 | RAB9A (0.65) | NPC1RAB9AHDAC6HDAC8HDAC1 | |
| SCHEMBL6797269 | 0.64 | NPC1 (0.56) | NPC1RAB9AHDAC6HDAC8HDAC1 | |
| SCHEMBL5120704 | 0.64 | RAB9A (1.00) | NPC1RAB9AHDAC6HDAC8HDAC1 | |
| SCHEMBL38651175 | 0.63 | RAB9A (0.73) | NPC1RAB9AHDAC6HDAC8HDAC1 | |
| SCHEMBL4805215 | 0.63 | RAB9A (0.83) | NPC1RAB9AHDAC6HDAC8HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169598-A1 | HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORS | 2681603 ONTARIO INC. (CA) | 2022-06-02 | — | — | US | disclosed |
| WO-2020194272-A1 | HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORS | 2681603 ONTARIO INC. (CA) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169598-A1 | HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC11 | NPC1 232/4885RAB9A 1007/4885HDAC6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.